Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering (IMRX) has 3 years of Revenue data on record, last reported at $455.0 in Q4 2022.

  • For Q4 2022, Revenue fell 99.76% year-over-year to $455.0; the TTM value through Sep 2023 reached $455.0, down 99.91%, while the annual FY2022 figure was $316952.0, 84.76% down from the prior year.
  • Revenue reached $455.0 in Q4 2022 per IMRX's latest filing, down from $38380.0 in the prior quarter.
  • Across five years, Revenue topped out at $748200.0 in Q1 2021 and bottomed at $455.0 in Q4 2022.
  • Average Revenue over 3 years is $374456.3, with a median of $335860.5 recorded in 2021.
  • Peak YoY movement for Revenue: dropped 29.37% in 2021, then plummeted 99.76% in 2022.
  • A 3-year view of Revenue shows it stood at $665080.0 in 2020, then crashed by 71.49% to $189591.0 in 2021, then tumbled by 99.76% to $455.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Revenue were $455.0 in Q4 2022, $38380.0 in Q3 2022, and $94419.0 in Q2 2022.